Best Oncology Companies in Seattle, United States
The 47 best Oncology companies in Seattle, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Sana Biotechnology.
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Oncology companies in Seattle
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Web popularity | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Sana Biotechnology Developer of engineered cell therapies for treating various human diseases | $821M | 73 mo ago | Public | 328 328 → 258 (-21%) | Steve Harr Co-Founder & CEO | Top 5M | 361 patents Engineered cell therapies and gene delivery platforms for regenerative medicine. | — |
| 2 | Umoja Biopharma Developer of cancer therapeutics | $263M | 19 mo ago | Series C | 168 | Michael Jensen Co-Founder | Top 5M | 132 patents Lentiviral vector manufacturing and engineered stem cell therapies for immuno‑oncology | — |
| 3 | Silverback Therapeutics Stealth mode immuno-oncology biotech startup | $211M | 70 mo ago | Public | 17 | Peter Thompson Co-Founder | — | 143 patents Develops small‑molecule kinase inhibitors and antibody‑drug conjugates for oncology targets. | — |
| 4 | Outpace Bio Developer of T-cell therapies for cancer treatment | $200M | 24 mo ago | Series B | 48 48 → 73 (+52%) | Scott Boyken Co-Founder | Top 10M | — | — |
| 5 | Callio Therapeutics Developer of multi-payload antibody-drug conjugates for cancer treatment | $187M | 17 mo ago | Series A | — | Jerome Kirkup Co-Founder & Chief Scientific Officer | — | — | — |
| 6 | Chinook Therapeutics Developer of therapeutics for treating kidney diseases | $180M | 71 mo ago | Acquired | 138 | Eric Dobmeier CEO & President | — | — | — |
| 7 | Calypso Medical Technologies Real-time localization technology for Oncology and radiation therapy | $148M | 185 mo ago | Acqui-Hired | 3,361 3,361 → 7,594 (+126%) | — | Top 1M | — | — |
| 8 | calypso medical Calypso Medical develops tumor localization systems designed to accurately and objectively track the location… | $148M | 185 mo ago | Acqui-Hired | 175 | — | — | — | — |
| 9 | OncoResponse Developer of immunotherapies for the treatment of cancer 64Funding top 20%Moat top 21%Patents top 24%Innovation top 27% All 8 signals ▾Fundingtop 20% Moattop 21% Patentstop 24% Innovationtop 27% Growthtop 28% Talentbottom 49% Globalbottom 42% Marketbottom 38% Funding: Raised $144M across 10 rounds · 10 rounds over 11 yrs (0.9/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 56 patents rank vs industry peers · Fliar Intelligence Index 64/100 | $144M | 15 mo ago | Series D | 33 | Clifford Stocks Founder & CEO | — | 56 patents LILRB2 immune‑checkpoint antibodies for cancer immunotherapy | — |
| 10 | CTI BioPharma Developer of targeted small molecule therapeutics for blood cancer | $132M | 110 mo ago | Acquired | 25 | — | — | 64 patents Novel heterocyclic small‑molecule therapeutics for hematologic cancers, GVHD, and viral infections | — |
| 11 | Blaze Bioscience Biotechnology company improving cancer patient lives through Tumor Paint technology | $124M | 30 mo ago | Series D | 27 | — | Top 50M | 157 patents Patents concentrated in chemistry & materials | — |
| 12 | Nohla Therapeutics Provider of stem-cell transplants with umbilical cord blood as an alternative to bone-marrow transplants | $120M | 97 mo ago | Deadpooled | 48 | — | — | — | — |
| 13 | VentiRx Developing small molecule product candidates targeting Toll-like receptor 8 (TLR8) for cancer | $120M | 142 mo ago | Acquired | 15 | — | — | — | — |
| 14 | immune design Immune Design develops vaccines and therapeutics for the prevention and treatment of infectious diseases. | $101M | 146 mo ago | Acquired | 50 | — | — | 256 patents Engineered viral vectors for cancer immunotherapy delivering cytokine and replicon RNA | — |
| 15 | Bonum Therapeutics Manufacturer of cytokine based drugs 45Funding top 22%Talent bottom 49%Tech bottom 45%Global bottom 43% All 5 signals ▾Fundingtop 22% Talentbottom 49% Techbottom 45% Globalbottom 43% Marketbottom 36% Funding: Raised $93.0M across 2 rounds · 2 rounds over 4 yrs (0.5/yr) Talent: 1 named leader on record · 1 C-suite/founder profile curated rank vs industry peers · Fliar Intelligence Index 45/100 | $93M | 4 mo ago | Series B | 54 | John Mulligan Founder & CEO | Top 50M | — | — |
| 16 | Nativis Developer of a therapeutic device for the treatment of cancer | $64M | 93 mo ago | Series B | 13 | — | — | 81 patents Wireless electromagnetic coil systems for targeted cancer therapy, especially glioblastoma treatment. | — |
| 17 | Theraclone Sciences Discovering human monoclonal antibodies for safe and effective therapeutic product development | $61M | 135 mo ago | Series B | 19 | Clifford J Stocks CEO | — | 225 patents Broadly neutralizing HIV‑1 envelope (Env) trimer monoclonal antibody therapeutics | — |
| 18 | Aptevo Therapeutics Developing T-cell cytotoxicity targeted immunotherapeutic drugs primarily for cancer and hematology | $57M | 16 mo ago | Public | 45 45 → 56 (+24%) | Marvin White President and CEO | Top 10M | — | — |
| 19 | Good Therapeutics Developer of protein-based drugs for cancer | $37M | 55 mo ago | Acquired | 23 | — | — | — | — |
| 20 | HDT Bio Developer of immunotherapy for the treatment of cancer & infectious diseases | $31M | 14 mo ago | Seed | 32 32 → 54 (+69%) | — | Top 50M | — | 1 award |
| 21 | SEngine Precision Medicine Provider of precision medicine platform based on patient-derived organoids | $27M | 41 mo ago | Series A | 26 | — | Top 50M | — | — |
| 22 | EMulate Therapeutics Developer of radiofrequency based devices for treatment of cancers | $23M | 82 mo ago | Public | 13 | Bennett M. Butters Founder | — | — | — |
| 23 | OncoGenex Oncogenex develops novel therapeutics targeting mechamisms of treatment resistance in cancer | $22M | 199 mo ago | Acqui-Hired | 12 | — | — | 3 patents Formulation technologies for antisense oligonucleotide therapeutics | — |
| 24 | Aminex Therapeutics Immuno-oncology company developing novel therapies to empower the immune system | $21M | 45 mo ago | Series B | 9 | — | — | — | — |
| 25 | Talus Provider of drug discovery platform for gene regulators | $20M | 16 mo ago | Seed | 15 | Alex Federation Co-Founder & CEO | Top 10M | 27 patents Automotive interior storage and organization systems for floor and cargo compartments | — |
| 26 | Link Immunotherapeutics Developer of immunotherapeutics to treat cancer | $14M | 64 mo ago | Deadpooled | 15 | — | — | — | — |
| 27 | Accipiter Biosciences Developer of de novo protein therapies for complex diseases treatment | $13M | 9 mo ago | Seed | — | Javier Castellanos Co-Founder & CTO | Top 50M | — | — |
| 28 | Atossa Therapeutics Developer of drugs for treating breast cancer | $7M | 66 mo ago | Public | 10 | — | Top 10M | 166 patents Sustained‑release endocrine modulators and pulmonary drug formulations using heparin/N‑acetylcysteine. | — |
| 29 | Neoleukin Therapeutics Manufacturers of therapeutic proteins to treat immunological disorders | $5M | 186 mo ago | Acquired | 7 | Jonathan Drachman CEO & President | — | — | — |
| 30 | PETX Optimizing breast cancer therapy with advanced imaging technology | $5M | 17 mo ago | Funding Raised | 5 | Paul E. Kinahan Co-Founder | — | — | — |
| 31 | Abacus Bioscience Developer of immunotherapeutics for treating cancer and viral diseases | $4M | 42 mo ago | Series A | 7 | Edward Clark Founder and Chair | Top 50M | — | — |
| 32 | Modulus Therapeutics Developer of immune cell therapies for the treatment of solid tumors | $4M | 61 mo ago | Seed | 10 | Bryce Daines Co-Founder & CTO | — | — | — |
| 33 | OncoSenX Developer of lipid nanoparticle and plasmid DNA for cancer therapy | $3M | 60 mo ago | Seed | 13 | John Lewis Co-Founder | — | 4 patents In vivo CAR‑T gene therapy delivery for cancer immunotherapy | — |
| 34 | ISM Therapeutics US-based biopharma developing therapeutics based on inositol signaling molecules for cystic fibrosis, cancer… | $3M | 234 mo ago | Seed | — | Alexis Traynor-Kaplan Founder & CSO | — | — | — |
| 35 | Onconome Blood test to assess risk of developing colorectal cancer | $2M | 189 mo ago | Deadpooled | — | Ray Cairncross CEO | — | 7 patents Molecular diagnostic assays and biomarkers for colorectal cancer detection and prognosis | — |
| 36 | Alpine Immune Sciences Developer of immunotherapies to treat cancer and autoimmune disorders | $1M | 59 mo ago | Acquired | 126 | — | — | 330 patents Engineered ICOS ligand protein therapeutics for immune modulation in cancer treatment | — |
| 37 | RJS Biologics Developer of therapeutics for cancer treatment | $225K | 109 mo ago | Funding Raised | 8 | Stephen Mccraith Founder | — | — | — |
Top 12 Oncology companies in Seattle
#1
Series B · Seattle, Washington · founded 2021 · 54 employees$93Mraised▾
Manufacturer of cytokine based drugs
- Apr 2026Series B$26.9M
- Nov 2022Series A$93M
#2
Series D · Seattle, Washington · founded 2015 · 33 employees$143.6Mraised▾
Developer of immunotherapies for the treatment of cancer. The company uses a proprietary technology platform to discover human antibodies and an immune checkpoint inhibitor (CPI). The company’s lead candidate is OR2805 for the treatment of multiple tumor types.
- Apr 2025Series D$6M
- May 2023Grant (prize money)$13M
- May 2023Series D$14M
- Feb 2022Conventional Debt$50M
#3
Series C · Seattle, Washington · founded 2019 · 168 employees$263Mraised▾
Developer of cancer therapeutics. The company has developed in vivo cellular immunotherapy platform that uses gene therapy to target and attack cancer cells. The company's products include VivoVec that acts through the body’s lymphatic system, to produce cancer-fighting VivoCAR T cells. The company's proprietary RACR/CAR system is used to enhance the activity of VivoCAR T cells. The company's other product includes TumorTag which is used to tag targeted tumor cells/stromal elements.
- Jan 2025Series C$100M
- Jun 2021Series B$210M
- Nov 2020Series A$53M
#4
Series A · Seattle, Washington · founded 2024$187Mraised▾
Developer of multi-payload antibody-drug conjugates for cancer treatment. It develops next-generation antibody-drug conjugates (ADCs) with differentiated payload and linker technologies. This targeted delivery of drug combinations to tumor cells aims to maximize therapeutic benefit for cancer patients. A key focus is on HER2-targeted dual-payload ADCs, and the company is advancing these through clinical proof-of-concept. Research and early development leverage systems biology approaches. Clinical development programs are managed from initial design through to global regulatory approvals. Business development activities include partnerships across multiple therapeutic areas and modalities.
- Mar 2025Series A$187M
#5
Seed · Seattle, Washington · founded 2023$12.7Mraised▾
Developer of de novo protein therapies for complex diseases treatment. These single-agent biologics are custom-engineered to engage multiple pathways. The biologics combine multiple mechanisms in one stable protein molecule. Therapeutic candidates activate more than one cell-surface receptor on the same cell. The platform uses computational methods to create customizable, multifunctional proteins. The company advances a pipeline in autoimmunity and oncology.
- Nov 2025Seed$12.7M
#6
Seed · Seattle, Washington · founded 2018 · 32 employees$30.6Mraised▾
HDT Bio is a developer of immunotherapy for the treatment of cancer & infectious diseases. It enhances the body's immunity power to fight against cancer disease. It increases tumor junctions and improves the disruptive capability. It helps in the tumor penetrance and therefore improves the efficacy, of diverse therapeutics including chemotherapeutics like Paclitaxel, Doxil, Cisplatin, antibodies, oncolytic viruses, and cell therapies. It helps in the treatment of breast cancer, ovarian cancer, and many more. It also provides solutions for pathogen agnostic therapeutics that offer solutions against gram-positive and gram-negative bacteria.
- May 2025Grant (prize money)$2.7M
- May 2025Grant (prize money)$1.6M
- May 2025Grant (prize money)$2.2M
- Apr 2025Grant (prize money)$2M
#7
Public · Seattle, Washington · founded 2016 · 45 employees$57.1Mraised▾
Developing T-cell cytotoxicity targeted immunotherapeutic drugs primarily for cancer and hematology. It is using its proprietary Adaptir platform technology to develop immuno-oncology candidates that focus on redirected T-cell cytotoxicity. It generate immunotherapeutics with mechanisms of action including targeted cytokine delivery, targeting two cell surface receptors or neutralization of multiple soluble proteins. Its pipeline has 4 oncology candidates with the lead Otlertuzumab which induces cell death of primary CLL cells-B-cell tumor lines and also induces NK-cell mediated ADCC and macrophage-mediated phagocytosis for chronic lymphocytic leukemia (CLL).
- Apr 2025Post IPO$2.1M
- Jan 2017Venture Debt$20M
- Aug 2016Conventional Debt$35M
#8
Seed · Seattle, Washington · founded 2020 · 15 employees$19.8Mraised▾
Provider of drug discovery platform for gene regulators. The company provides a functional proteomics platform MARMOT focused on studying full-length GRPs in an unmodified cellular environment. It allows the development of therapeutics against the disease-causing GRPs.
- Apr 2025Grant (prize money)$398.4K
- Feb 2025Grant (prize money)$2M
- Jul 2024Seed$11.2M
- Aug 2023Grant (prize money)$4.3M
#9
Series B · Seattle, Washington · founded 2020 · 48 employees$200Mraised▾
Developer of T-cell therapies for cancer treatment. The therapies include cell therapy producing controlled Cytokine X, CAR with counter- exhaustion mechanism, cell therapy producing controlled Cytokine Y, and drug-induced gene regulation. These therapies are developed by combining protein design and cell engineering and also with the help of protein design software that custom designs the new biological functions.
- Jul 2024Series B$144M
- Mar 2021Series A$30M
#10
Series D · Seattle, Washington · founded 2010 · 27 employees$123.7Mraised▾
Biotechnology company improving cancer patient lives through Tumor Paint technology. They are dedicated to making cancer detection, removal, and treatment sensitive, reliable, and accessible. They leverage their Tumor Paint technology, including the CANVAS imaging system, to achieve this goal. The company focuses on research and development in the biotechnology sector, specifically in oncology and medical imaging. Their work has a direct social impact by aiming to improve outcomes for cancer patients. They are involved in developing innovative solutions for cancer diagnosis and treatment, contributing to advancements in healthcare.
- Feb 2024Series D$8.1M
- Oct 2022Series D$25M
- Oct 2021Series D$15M
- Oct 2020Series C$10M
#11
Funding Raised · Seattle, Washington · founded 2012 · 5 employees$4.7Mraised▾
Optimizing breast cancer therapy with advanced imaging technology. They combine positron emission tomography and X-ray mammography to determine effective targeted therapies for breast cancer patients, avoiding delays and side effects. Their solution is valuable for testing new treatments in clinical trials. They are a research-focused organization developing innovative medical instruments. This is a B2B tech company focused on healthcare, specifically oncology. Their technology has a significant social impact by improving cancer treatment outcomes. They are developing a medical device for research use.
- Feb 2025Grant (prize money)$2M
- Jul 2017Grant (prize money)$359.9K
- Sep 2016Grant (prize money)$2M
- Aug 2013Grant (prize money)$406.6K
#12
Public · Seattle, Washington · founded 2018 · 328 employees$821Mraised▾
Developer of engineered cell therapies for treating various human diseases. Research focuses on repairing or controlling genes within cells and replacing damaged or missing cells to address underlying disease causes. Drug candidates target conditions including diabetes, cancers, and autoimmune disorders. The work involves cellular biology and machine learning to create therapeutic interventions.
- Jun 2020Series D$821M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
What Seattle researches in oncology
- Seattle Children\'s Hospital13
- Seattle University10
- Seattle Cancer Care Alliance5
- North Seattle College1
- Seattle Pacific University1
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.